Duyuru • May 06
FONAR Corporation, Annual General Meeting, Jun 17, 2026 FONAR Corporation, Annual General Meeting, Jun 17, 2026. Location: at the hilton long island huntington hotel, 598 broadholow road, melvile, new york 11747, United States Duyuru • Feb 10
FONAR Corporation announced delayed 10-Q filing On 02/09/2026, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. New Risk • Dec 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€81.8m market cap, or US$96.0m). Buy Or Sell Opportunity • Dec 31
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to €15.60. The fair value is estimated to be €12.71, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.6% over the last 3 years. Earnings per share has declined by 7.2%. Duyuru • Sep 13
FONAR Corporation announced delayed annual 10-K filing On 09/12/2025, FONAR Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Jul 10
Timothy Damadian along with management team and Board of Directors of FONAR Corporation and third parties proposed to acquire remaining 94.99% stake in FONAR Corporation (NasdaqCM:FONR). Timothy Damadian along with management team and Board of Directors of FONAR Corporation and third parties proposed to acquire remaining 94.99% stake in FONAR Corporation (NasdaqCM:FONR) on July 7, 2025. The Proposed Acquisition Group currently beneficially owns approximately 5.01% of the outstanding FONAR Stock.
The Board of Directors of FONAR Corporation formed a special committee consisting of independent and disinterested directors of the Board, who will carefully review the proposal to determine the course of action that is in the best interests of FONAR Corporation and all shareholders. Duyuru • Jul 03
FONAR Corporation Appoints Robert M. Carrino as an Independent Director FONAR Corporation announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the company’s board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position. Mr. Carrino is a partner at CFGI, LLC in New York City, where he leads the firm’s SPAC practice. He provides complex accounting and consulting services to both public and private companies. Prior to joining CFGI, Mr. Carrino was an audit manager at KPMG, LLP’s Metro New York Long Island Office. Mr. Carrino, a Certified Public Accountant, earned the degree of Bachelor of Science in Business Administration with a concentration in accounting from Western New England University. Duyuru • Jun 25
FONAR Corporation Announces Intention of Claudette J.V. Chan to Retire from the Board of Directors and Secretary, Effective June 19, 2025 On June 18, 2025, Claudette J.V. Chan, a member of the Board of Directors and the Secretary of FONAR Corporation, notified the Company of her intention to retire from the Company's Board of Directors, and to retire as Secretary of the Company, effective June 19, 2025. Ms. Chan did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Duyuru • Apr 23
FONAR Corporation, Annual General Meeting, May 19, 2025 FONAR Corporation, Annual General Meeting, May 19, 2025. Location: hilton long island huntington hotel, 598 broadhollow road, melville, new york 11747, United States Duyuru • Feb 15
FONAR Corporation announced delayed 10-Q filing On 02/14/2025, FONAR Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Reported Earnings • Nov 15
First quarter 2025 earnings released First quarter 2025 results: Revenue: US$25.0m (down 3.4% from 1Q 2024). Net income: US$3.14m (down 20% from 1Q 2024). Profit margin: 13% (down from 15% in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year and the company’s share price has also fallen by 1% per year. New Risk • Oct 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €89.7m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€89.7m market cap, or US$98.1m). New Risk • Oct 01
New major risk - Revenue and earnings growth Earnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Sep 29
Full year 2024 earnings released: EPS: US$1,637 (vs US$1,425 in FY 2023) Full year 2024 results: EPS: US$1,637 (up from US$1,425 in FY 2023). Revenue: US$102.9b (up 4.3% from FY 2023). Net income: US$10.6b (up 13% from FY 2023). Profit margin: 10% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Duyuru • Sep 28
FONAR Corporation to Report Fiscal Year 2024 Results on Sep 27, 2024 FONAR Corporation announced that they will report fiscal year 2024 results on Sep 27, 2024 Reported Earnings • May 17
Third quarter 2024 earnings released: EPS: US$0.28 (vs US$0.55 in 3Q 2023) Third quarter 2024 results: EPS: US$0.28 (down from US$0.55 in 3Q 2023). Revenue: US$25.7m (up 1.2% from 3Q 2023). Net income: US$1.87m (down 49% from 3Q 2023). Profit margin: 7.3% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 1% per year. Duyuru • Apr 09
FONAR Corporation, Annual General Meeting, May 20, 2024 FONAR Corporation, Annual General Meeting, May 20, 2024, at 10:00 US Eastern Standard Time. Location: The Hilton Long Island Huntington Hotel, 598 Broadhollow Road, Melville New York United States Agenda: To elect five Directors to the Board of Directors; to approve, on an advisory basis, the compensation of the Company’s named executive officers; to recommend, on an advisory basis, whether the advisory stockholder vote to approve the compensation of the Company’s named executive officers be taken every year, every two years, or every three years; to ratify the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2024; and to transact such other business as may properly come before the meeting. Reported Earnings • Feb 16
Second quarter 2024 earnings released: EPS: US$0.59 (vs US$0.32 in 2Q 2023) Second quarter 2024 results: EPS: US$0.59 (up from US$0.32 in 2Q 2023). Revenue: US$25.4m (up 4.7% from 2Q 2023). Net income: US$3.76m (up 76% from 2Q 2023). Profit margin: 15% (up from 8.8% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 9% per year. Reported Earnings • Nov 16
First quarter 2024 earnings released First quarter 2024 results: Revenue: US$25.8m (up 11% from 1Q 2023). Net income: US$4.11m (up 110% from 1Q 2023). Profit margin: 16% (up from 8.4% in 1Q 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Nov 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €14.90, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 30x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.1% over the past three years. New Risk • Oct 03
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €95.3m (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€95.3m market cap, or US$100.0m). Reported Earnings • Sep 29
Full year 2023 earnings released: EPS: US$1.37 (vs US$1.78 in FY 2022) Full year 2023 results: EPS: US$1.37 (down from US$1.78 in FY 2022). Revenue: US$98.6m (up 1.1% from FY 2022). Net income: US$9.38m (down 21% from FY 2022). Profit margin: 9.5% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: US$25.4m (up 3.5% from 3Q 2022). Net income: US$3.69m (up 69% from 3Q 2022). Profit margin: 14% (up from 8.9% in 3Q 2022). The increase in margin was primarily driven by higher revenue. Reported Earnings • Feb 15
Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.57 in 2Q 2022) Second quarter 2023 results: EPS: US$0.34 (down from US$0.57 in 2Q 2022). Revenue: US$24.3m (flat on 2Q 2022). Net income: US$2.23m (down 42% from 2Q 2022). Profit margin: 9.2% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year. Reported Earnings • Nov 16
First quarter 2023 earnings released First quarter 2023 results: Revenue: US$23.2m (down 2.3% from 1Q 2022). Net income: US$2.05m (down 45% from 1Q 2022). Profit margin: 8.8% (down from 16% in 1Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 3% per year. Recent Insider Transactions • Oct 05
Key Executive recently bought €67k worth of stock On the 30th of September, Luciano Bonanni bought around 5k shares on-market at roughly €14.34 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Luciano's only on-market trade for the last 12 months. Duyuru • Sep 30
FONAR Corporation (NasdaqCM:FONR) announces an Equity Buyback for $9 million worth of its shares. FONAR Corporation (NasdaqCM:FONR) announces a share repurchase program. Under the program, the company will repurchase its own shares. The program has no expiration date.
On September 26, 2022, the company announced that the Board of Directors has approved up to $9 million to be repurchased under the program. Reported Earnings • Sep 29
Full year 2022 earnings released: EPS: US$1.71 (vs US$1.46 in FY 2021) Full year 2022 results: EPS: US$1.71 (up from US$1.46 in FY 2021). Revenue: US$97.6m (up 8.5% from FY 2021). Net income: US$11.9m (up 22% from FY 2021). Profit margin: 12% (up from 11% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 8% per year. Duyuru • Aug 13
FONAR Corporation Announces Passing of Its Chairman of the Board of Directors, Raymond V. Damadian Fonar Corporation and it’s board of directors reported the passing of its Chairman of the Board of Directors, Raymond V. Damadian, on August 3, 2022. Highlights of the life of Dr. Raymond Damadian: Founded FONAR Corporation (1978), the first company in the MRI industry, maker of the QED80, the world’s first MRI scanner (1980); Conceived the idea for MRI in 1969; Made the discovery in 1970 that is the basis for the making of every MRI image ever produced, the foundation of the MRI industry. Dr. Damadian discovered that there is a marked difference in the relaxation times of NMR (MRI) signals from normal and cancerous tissues of the same type, as well as from different types of normal tissues. This discovery, published in the peer-reviewed journal ‘Science’ in March 1971 marked the beginning of the MRI industry.; Awarded the world’s first MRI patent (filed in March 1971). This patent was upheld in FONAR’s successful lawsuit against General Electric in 1995.; Built the world’s first MRI scanner, Indomitable, which produced the world’s first MRI scan on July 3, 1977.; Awarded The National Medal of Technology by President Ronald Reagan in 1988.; Inducted into the National Inventors Hall of Fame in 1989, joining a select group of renowned pioneers, including Orville and Wilbur Wright, Henry Ford, Thomas Edison and Alexander Graham Bell. Received the Excellence in Medicine award from the Chiari & Syringomyelia Foundation (CSF) in London England on November 10, 2018. Reported Earnings • May 17
Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.55 in 3Q 2021) Third quarter 2022 results: EPS: US$0.33 (down from US$0.55 in 3Q 2021). Revenue: US$24.6m (up 6.4% from 3Q 2021). Net income: US$2.19m (down 41% from 3Q 2021). Profit margin: 8.9% (down from 16% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Duyuru • Apr 09
FONAR Corporation, Annual General Meeting, May 23, 2022 FONAR Corporation, Annual General Meeting, May 23, 2022. Location: Double Tree Hotel, Wilmington Downtown, 700 King Street, Wilmington, Delaware 19801 (302-655-0400) New York United States Agenda: To elect five Directors to the Board of Directors; To approve, on an advisory basis, the compensation of the Company’s named executive officers; To ratify the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2022; To transact such other business as may properly come before the meeting. Buying Opportunity • Mar 12
Now 20% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be US$19.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 27% per annum over the last 3 years. Reported Earnings • Feb 15
Second quarter 2022 earnings: Revenues in line with analyst expectations Second quarter 2022 results: Revenue: US$24.5m (up 16% from 2Q 2021). Net income: US$3.84m (up 29% from 2Q 2021). Profit margin: 16% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Reported Earnings • Sep 29
Full year 2021 earnings released: EPS US$1.51 (vs US$1.20 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$89.9m (up 4.9% from FY 2020). Net income: US$10.2m (up 30% from FY 2020). Profit margin: 11% (up from 9.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • May 15
Third quarter 2021 earnings released: EPS US$0.53 (vs US$0.18 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$23.1m (up 6.5% from 3Q 2020). Net income: US$3.69m (up 207% from 3Q 2020). Profit margin: 16% (up from 5.6% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Mar 03
New 90-day high: €16.60 The company is up 5.0% from its price of €15.80 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period. Reported Earnings • Feb 19
Second quarter 2021 earnings released: EPS US$0.43 (vs US$0.45 in 2Q 2020) The company reported a soft second quarter result with weaker revenues, although earnings and profit margins were flat. Second quarter 2021 results: Revenue: US$21.2m (down 1.3% from 2Q 2020). Net income: US$2.97m (flat on 2Q 2020). Profit margin: 14% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 29
New 90-day low: €14.00 The company is down 25% from its price of €18.60 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. Duyuru • Sep 30
FONAR Corporation announced delayed amended 10-K filing On 09/29/2020, FONAR Corporation announced that they will be unable to file their amended 10-K by the deadline required by the SEC. Reported Earnings • Sep 29
Full year earnings released - EPS €1.20 Over the last 12 months the company has reported total profits of US$7.86m, down 46% from the prior year. Total revenue was US$85.7m over the last 12 months, down 1.7% from the prior year. Profit margins were 9.2%, which is lower than the 17% margin from last year. The decrease in margin was primarily driven by higher expenses. 